

V Tesar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11562966/publications.pdf>

Version: 2024-02-01

42
papers

2,583
citations

257450

24
h-index

276875

41
g-index

42
all docs

42
docs citations

42
times ranked

3303
citing authors

#	ARTICLE	IF	CITATIONS
1	Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. <i>Kidney International</i> , 2022, 102, 160-172.	5.2	25
2	Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy. <i>Kidney International</i> , 2021, 99, 1179-1188.	5.2	47
3	Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury. <i>Journal of Nephrology</i> , 2021, 34, 1263-1270.	2.0	3
4	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1002-1009.	0.7	66
5	Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. <i>Kidney International</i> , 2020, 98, 1009-1019.	5.2	35
6	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179.	5.2	13
7	Matrix Metalloproteinases and Their Tissue Inhibitors: an Evaluation of Novel Biomarkers in ANCA-Associated Vasculitis. <i>Folia Biologica</i> , 2019, 65, 227-236.	0.6	1
8	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1583-1594.	0.9	940
9	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 67, 576-584.	1.9	19
10	The MEST score provides earlier risk prediction in IgA nephropathy. <i>Kidney International</i> , 2016, 89, 167-175.	5.2	190
11	Increased Levels of Soluble ST2 in Patients with Active Newly Diagnosed ANCA-Associated Vasculitis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-5.	3.0	11
12	Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A. <i>Lupus</i> , 2014, 23, 69-74.	1.6	28
13	AB0177: Toll-Like Receptors - Differences between Healthy Control, ANCA Associated Vasculitis and Lupus Kindeys - Preliminary Pilot Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 861.3-861.	0.9	0
14	The retrospective analysis of 343 Czech patients with IgA nephropathy--one centre experience. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1492-1498.	0.7	29
15	Common Carotid Wall Shear Stress and Carotid Atherosclerosis in End-Stage Renal Disease Patients. <i>Physiological Research</i> , 2012, 61, 355-361.	0.9	14
16	Recent news in the treatment of lupus nephritis. <i>Minerva Medica</i> , 2012, 103, 235-51.	0.9	2
17	Association of advanced vasculopathy and transforming growth factor-beta1 gene expression with immunoglobulin A nephropathy progression. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 573-579.	0.7	15
18	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. <i>Rheumatology</i> , 2011, 50, 899-905.	1.9	89

#	ARTICLE	IF	CITATIONS
19	Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. <i>Lupus</i> , 2010, 19, 1281-1289.	1.6	111
20	Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre. <i>International Urology and Nephrology</i> , 2009, 41, 941-945.	1.4	16
21	Mechanisms of chronic heart failure development in end-stage renal disease patients on chronic hemodialysis. <i>Physiological Research</i> , 2009, 58, 613-621.	0.9	39
22	Pregnancy-Associated Plasma Protein a during Hemodialysis with Polyamide and Diacetate Cellulosic Membranes. <i>International Journal of Artificial Organs</i> , 2004, 27, 943-948.	1.4	4
23	Advanced Glycation End Products in Clinical Nephrology. <i>Kidney and Blood Pressure Research</i> , 2004, 27, 18-28.	2.0	48
24	Relationship of Pregnancy-Associated Plasma Protein-A to Renal Function and Dialysis Modalities. <i>Kidney and Blood Pressure Research</i> , 2004, 27, 88-95.	2.0	40
25	Increased Levels of Pregnancy-Associated Plasma Protein A Are Associated with Mortality in Hemodialysis Patients: Preliminary Results. <i>Blood Purification</i> , 2004, 22, 298-300.	1.8	25
26	The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 3040-3049.	0.7	187
27	Current treatment strategies in ANCA-positive renal vasculitis—lessons from European randomized trials. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2v-4.	0.7	57
28	Glycoxidation and inflammation in chronic haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2577-2581.	0.7	47
29	Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 38v-40.	0.7	16
30	Advanced Glycation End Products and Advanced Oxidation Protein Products in Hemodialyzed Patients. <i>Blood Purification</i> , 2002, 20, 531-536.	1.8	52
31	Soluble Adhesion Molecules and Cytokines in Patients with Myasthenia Gravis Treated by Plasma Exchange. <i>Blood Purification</i> , 2000, 18, 115-120.	1.8	22
32	Trace Elements in End-Stage Renal Disease. <i>Blood Purification</i> , 1999, 17, 187-198.	1.8	56
33	The effect of silibinin on experimental cyclosporine nephrotoxicity. <i>Renal Failure</i> , 1998, 20, 471-479.	2.1	25
34	Trace Elements in Hemodialysis and Continuous Ambulatory Peritoneal Dialysis Patients. <i>Blood Purification</i> , 1998, 16, 253-260.	1.8	61
35	Effect of 1 year cyclosporine a treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. <i>Lupus</i> , 1998, 7, 29-36.	1.6	59
36	Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 1662-1667.	0.7	68

#	ARTICLE	IF	CITATIONS
37	Influence of Plasma Exchange on Serum Levels of Cytokines and Adhesion Molecules in ANCA-Positive Renal Vasculitis. <i>Blood Purification</i> , 1998, 16, 72-80.	1.8	56
38	The Influence of Cyclosporin on Lipid Peroxidation and Superoxide Dismutase in Adriamycin Nephropathy in Rats. <i>Nephron</i> , 1997, 75, 464-468.	0.6	30
39	Antioxidant Enzymes - Superoxide Dismutase and Glutathione Peroxidase - in Haemodialyzed Patients. <i>Blood Purification</i> , 1996, 14, 257-261.	1.8	26
40	The influence of chronic ethanol administration on adriamycin-induced nephrotic syndrome in rats. <i>Alcohol and Alcoholism</i> , 1995, 30, 47-53.	1.6	2
41	Atrial Natriuretic Factor in Liver Cirrhosis - the Relation to Haemodynamic Parameters. <i>Hormone and Metabolic Research</i> , 1990, 22, 400-401.	1.5	1
42	Atrial Natriuretic Factor in Liver Cirrhosis - The Influence of Volume Expansion. <i>Hormone and Metabolic Research</i> , 1989, 21, 519-522.	1.5	8